Author

L. Hernandez Borrero

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

W. S. El-Deiry· 2 shared A. Lev· 1 shared D. T. Dicker· 1 shared J. Sanders· 1 shared J. Santiago· 1 shared K. E. Huntington· 1 shared L. Zhang· 1 shared L. Zhou· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

W. S. El-Deiry

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivSep 13, 2023

Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation

V. Tajiknia, M. Pinho-Schwermann, P. R. Srinivasan…·W. S. El-Deiry

This study shows that MRTX1133, a KRAS G12D inhibitor, synergizes with 5-FU or ONC212 to reduce tumor cell viability and pERK in CRC and pancreatic cancer cells, regardless of KRAS mutation status.

DOI 10.62347/dvxl1377

humanproteomics

𝕏 PostBluesky

Cancer BiologyeLifePeer-reviewedJul 29, 2021

A subset of CB002 xanthine analogues bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53

L. Hernandez Borrero, D. T. Dicker, J. Santiago…·W. S. El-Deiry

The paper identifies CB002 analogues that restore p53 signaling and target an S-phase checkpoint in p53-mutated tumors, inducing apoptosis and reducing proliferation without harming normal cells.

DOI 10.7554/elife.70429

humanproteomics

𝕏 PostBluesky